Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.48 USD | -0.63% | +3.09% | +25.15% |
Apr. 11 | Mizuho Securities Adjusts Price Target on Glaukos to $100 From $85, Maintains Neutral Rating | MT |
Apr. 11 | Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.15% | 4.99B | B+ | ||
+12.07% | 128B | A- | ||
-9.04% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+16.72% | 7.19B | C | ||
+7.17% | 3.4B | C- | ||
-1.36% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - | ||
-22.81% | 1.79B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GKOS Stock
- Ratings Glaukos Corporation